Fiera Capital Corp Decreases Holdings in Vaxcyte, Inc. $PCVX

Fiera Capital Corp reduced its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 353,842 shares of the company’s stock after selling 5,360 shares during the quarter. Fiera Capital Corp owned about 0.27% of Vaxcyte worth $11,503,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. AlphaQuest LLC acquired a new stake in shares of Vaxcyte in the 1st quarter worth $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Vaxcyte in the first quarter valued at about $35,000. CWM LLC boosted its holdings in Vaxcyte by 197.3% in the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after acquiring an additional 1,115 shares in the last quarter. IFP Advisors Inc boosted its holdings in Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after acquiring an additional 1,306 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Vaxcyte by 176.7% during the second quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock worth $70,000 after acquiring an additional 1,380 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Cowen reiterated a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective for the company. Finally, BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Vaxcyte Trading Down 1.2%

Shares of NASDAQ PCVX opened at $45.55 on Friday. The company has a 50 day simple moving average of $39.17 and a two-hundred day simple moving average of $35.33. The stock has a market cap of $5.96 billion, a price-to-earnings ratio of -9.41 and a beta of 1.07. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $98.17.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same period in the previous year, the firm earned ($0.83) EPS. Analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.